Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Rhea-AI Summary

Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes (T2D), has announced it will release its fourth quarter and full year 2024 financial results on March 3, 2025, at 4:30 p.m. ET. The company will also provide business updates during the event.

A live webcast of the conference call will be available in the 'Events' section of Fractyl's investor relations website, with a replay option available after the event.

News Market Reaction – GUTS

-0.70%

-0.70% Session move

In the trading session that priced this news, GUTS declined 0.70%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m. ET.

A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.

Contacts 

Media Contact 
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com. 978.760.5622

Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

FAQ

When will Fractyl Health (GUTS) release Q4 and full year 2024 earnings?

Fractyl Health will release its Q4 and full year 2024 financial results on March 3, 2025, at 4:30 p.m. ET.

How can investors access Fractyl Health's (GUTS) Q4 2024 earnings call?

Investors can access the live webcast through the 'Events' section of Fractyl's website at https://ir.fractyl.com/. A replay will be available after the event.

What therapeutic areas does Fractyl Health (GUTS) focus on?

Fractyl Health focuses on developing metabolic therapeutics for the treatment of obesity and type 2 diabetes (T2D).

Will Fractyl Health (GUTS) provide business updates during their March 2025 earnings call?

Yes, Fractyl Health will provide business updates along with their fourth quarter and full year 2024 financial results on March 3, 2025.